Trials / Completed
CompletedNCT04320745
A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male Participants
A Phase IV, Multi-center, Open-label, Single-arm 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Study of 16 Weeks Treatment With Androderm® in Hypogonadal Men
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 168 (actual)
- Sponsor
- Allergan · Industry
- Sex
- Male
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the effect of a once daily Androderm® dose on Blood Pressure (BP) in adult hypogonadal men as measured by 24-hour ABPM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Androderm® | Androderm® transdermal dose. |
Timeline
- Start date
- 2020-05-19
- Primary completion
- 2021-06-24
- Completion
- 2021-06-24
- First posted
- 2020-03-25
- Last updated
- 2022-07-12
- Results posted
- 2022-07-12
Locations
41 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04320745. Inclusion in this directory is not an endorsement.